These are important guidelines relating to type 2 diabetes and recent alerts which may have a bearing on current management.
For the most up to date guidance on a specific topic, see NICE Evidence search
The National Institute for Health and Care Excellence, also known as NICE, was set up in the UK in 1999.
Its main aim was to reduce the variation in the availability and quality of services in the NHS and to resolve uncertainties about how best to manage certain conditions.
Here you will find a list of the main areas covered by NICE guidance in relation to type 2 diabetes
‘TA’ refers to technology appraisals
‘CG’ refers to clinical guidance
‘PH’ refers to public health guidance
Education and self-management
Prevention of diabetes
Diabetes in pregnancy
2008: Antenatal care (CG62)
National service framework guidance
The National service framework is a body which sets quality standards about how care should be delivered within the NHS.
Here you will find links to the main National service framework publications related to type 2 diabetes.
2010: Six years on: delivering the diabetes national service framework
2007: Working together for better diabetes care
2006: Diabetes commissioning toolkit
2006: How to assess structured diabetes education: an improvement toolkit for commissioners and local diabetes communities
2003: National service framework for diabetes: delivery strategy
2001: National service framework for diabetes: standards
2001: Listening to diabetes service users qualitative findings for the diabetes national service framework
SIGN guidance from the Scottish intercollegiate Guidelines Network
SIGN was founded in 1993 to improve the quality of care in Scotland by developing and disseminating evidence based guidance for the NHS in Scotland.
There is currently one main document published by SIGN in relation to diabetes.
Royal College Guidelines
The MHRA is the Medicines and Healthcare products Regulatory Agency. It is a government agency which aims to promote and maintain the safety of medicines and medical devices.
When a safety concern is raised about a medication used in diabetes, the MHRA publish very useful summaries of the evidence and what action should be taken.
Information aimed at patients
Information aimed at health professionals